EUCTR2009-012855-90-CZ进行中（未招募）不适用
Randomised, placebo-controlled, double-blind, parallel-group, comparative study of two topical products for the treatment of psoriasis
Jelfa SA0 个研究点开始时间: 2009年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •clinical diagnosis of chronic, stable, mild to moderate plaque psoriasis affecting 5% to 20% of body surface area and PASI<12
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •erythrodermic psoriasis
- •guttate psoriasis
- •pustular psoriasis
- •application of topical corticosteroids 2 weeks before enrollment to the study
- •systemic biologic therapy
- •spontaneous improvement during recent 2 months
- •rapidly deteriorating psoriasis in recent 2 months
- •uncontrolled systemic disease
- •known hypersensitivity to any test products
- •pregnancy and breasfeeding
研究者
相似试验
进行中（未招募）
1 期
Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipatioEUCTR2017-000657-39-DEDevelco Pharma Schweiz AG1,492
进行中（未招募）
1 期
Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipation.EUCTR2017-000657-39-PTDevelco Pharma Schweiz AG563
进行中（未招募）
不适用
Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipation.Opioid-induced bowel dysfunction (OBD) involves not only constipation, but also a constellation of symptoms including incomplete evacuation, bloating, abdominal distension, and increased gastric reflux.Constipation is an almost inevitable consequence of opioid use in malignant and non-malignant disease states, and one of the side effects of opioids to which few patients develop tolerance.MedDRA version: 16.1Level: LLTClassification code 10071128Term: Opioid induced constipationSystem Organ Class: 100000004856EUCTR2012-004311-31-PLDevelco Pharma Schweiz AG306
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled, parallel group trial to confirm the efficacy, safety and tolerability of Ginkgo biloba Special Extract EGb 761® in patients suffering from Mild Mental Impairment (MMI) - NAEUCTR2005-005765-11-EEDr. Willmar Schwabe GmbH & Co. KG300
进行中（未招募）
1 期
Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipatioOpioid induced constipationMedDRA version: 20.0Level: LLTClassification code 10071128Term: Opioid induced constipationSystem Organ Class: 100000004856EUCTR2017-000657-39-GBDevelco Pharma Schweiz AG563